Industry says it will remain vigilant to ensure that the European Medicines Agency’s new role in agreeing on marketing authorization application filing dates does not stray from its intended purpose of improving dossier quality.
Industry says it will remain vigilant to ensure that the European Medicines Agency’s new role in agreeing on marketing authorization application filing dates does not stray from its intended purpose of improving dossier quality.